Farmak International Secures First Marketing Authorization in China for MRI Contrast Agent
Farmak International is proud to announce a significant milestone: the successful registration of our MRI contrast agent in the People's Republic of China.
Here you will find the latest updates and news from Farmak International. Discover important announcements, breakthroughs in research, and developments in our ongoing commitment to advancing healthcare. Stay informed about our milestones as we continue to make a positive impact on global health.
Farmak International is proud to announce a significant milestone: the successful registration of our MRI contrast agent in the People's Republic of China.
On 19 September 2024, Farmak Pharmaceuticals UK Ltd, a subsidiary of Farmak International, where it holds a majority share, completed the acquisition of a group of generic pharmaceutical companies.
Farmak AG are to change branding and appearance to Farmak International. This strategic move marks a significant milestone in our company's evolution and aligns with our long-term vision for growth and global expansion.
As of 27 March 2024, Farmak AG has successfully finalized its acquisition of Symphar Sp. z o.o., becoming the sole owner of the Polish pharmaceutical company through a cash transaction.
Please check your email inbox for our corporate materials.
OK, Got ItPlease fill all the fields marked by *